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The involvement of polypeptide chain-releasing factor eRF3 in translation termination and mRNA
decay is well established. Moreover, the ﬁnding that the proteolytically processed isoform of eRF3
(p-eRF3) interacts with inhibitors of apoptosis proteins (IAPs) to activate caspase, implies that
eRF3 is a cell death regulator. However, the protease(s) responsible for p-eRF3 production and
how p-eRF3 regulates apoptosis remain unknown. Here, we show that calpain mediates p-eRF3 pro-
duction in vitro and in living cells. p-eRF3 is produced in cells treated with ER stressors in a
calpain-dependent manner. These ﬁndings suggest that p-eRF3 is a novel regulator of
calpain-dependent cell death.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
It is generally accepted that eRF3/GSPT works with another
releasing factor, eRF1, to execute translation termination. Two sub-
types of eRF3, eRF3a/GSPT1 and eRF3b/GSPT2, were identiﬁed in
mammals [1,2]. Functional domains of eRF3/GSPT are separated
into an amino-terminal unstructured domain (N-domain) and a
translation elongation factor eEF1A-like GTP-binding domain
(C-domain) [2,3]. The C-domain is essential for the interaction with
eRF1 to terminate translation, in which eRF3/GSPT hydrolyzes GTP
to accelerate the polypeptide chain releasing reaction catalyzed by
the ribosome [4,5]. eRF3/GSPT also plays a pivotal role in the initi-
ation of mRNA decay through interaction with the poly(A)-binding
protein PABPC1 in its N-domain [6–8]. The interaction between
eRF3/GSPT and PABPC1 contributes to translation activation by
efﬁcient recycling of the terminating ribosome to the next round
of translation initiation [9,10]. These studies deﬁne eRF3/GSPT as
a multifunctional regulator of gene expression.A previous study identiﬁed a proteolytically processed isoform
of eRF3a/GSPT1 (termed p-eRF3) as a binding partner of inhibitors
of apoptosis proteins (IAPs), and showed that p-eRF3 promotes the
activation of caspase by the titration of IAPs, which leads to the lib-
eration of caspases from IAP inhibition [11]. p-eRF3 is generated by
cleavage at residue 73A of eRF3a/GSPT1, the N-terminus of which
exposes the IAP-binding motif (IBM). Since the N-terminally
exposed alanine of IBM is essential for the interaction with IAPs,
p-eRF3 but not full-length eRF3 interacts with IAPs to activate cas-
pases [12,13]. When p-eRF3 is produced by the cleavage, the
nuclear export signal (NES) of eRF3a/GSPT1, which is located
immediately upstream of the cleavage site A73, is removed from
eRF3a/GSPT1 [14]. This enables p-eRF3 to localize in the nucleus
as well as the cytoplasm and to interact efﬁciently with the nuclear
ARF tumor suppressor [14]. These ﬁndings reveal that eRF3
becomes a regulator of cell death upon cleavage at 73A. To eluci-
date the physiological signiﬁcance of p-eRF3, we have attempted
to determine stimuli for p-eRF3 production [15]. To date, we have
examined apoptosis-inducing conditions, in which other
IBM-containing proteins, Omi/HtrA2 and Smac/DIABLO, function
to promote apoptosis, but p-eRF3 was not produced in these con-
ditions [15]. Since Omi/HtrA2 and Smac/DIABLO are mitochondrial
proteins and promote mitochondria-dependent apoptosis, p-eRF3
may not function in the mitochondria-dependent apoptosis path-
way, consistent with the cytoplasmic localization of eRF3 [16,17].
We also found that the other processed isoform of eRF3
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produced during apoptosis [15].
Here, we demonstrate that calpains, calcium-dependent cys-
teine proteases, are responsible for p-eRF3 production. The cal-
pains are a conserved family of cysteine proteases involved in
several physiological processes, including apoptosis and cell sur-
vival [18]. We also show that calpain activity is necessary for
p-eRF3 production in living cells. These ﬁndings characterize
p-eRF3 as a novel regulator of calpain-dependent cell death.
2. Materials and methods
2.1. Cell culture and transfection
THP-1 cells were cultured in RPMI-1640 (Nissui) supplemented
with 5% fetal bovine serum (Sigma) and maintained at 37 C in 5%
CO2. SK-N-SH and HEK293T cells were cultured in DMEM supple-
mented with 5% fetal bovine serum (Sigma). THP-1 cells were
transfected with plasmid using Neon™ Transfection System
(Invitrogen). HEK293T cells were transfected with plasmids using
polyethylenimine Max (Polysciences, Inc.).
2.2. Plasmid
To construct pCMV-MycFLAG-Ub-hGSPT1/eRF3a(A73G), the
corresponding region of human GSPT1 cDNA was ampliﬁed by
inverse PCR using primer pairs YH30 (50-GTG CCC AAC GTC CAC
GCC GCC GAG TTC GTG-30)/YH31 (50-GAA GGG CTT GCC GTT GAC
GTT GAG TTG CCG-30), and pCMV-MycFLAG-Ub-hGSPT1 [15] as a
template. Other eRF3-expressing constructs used in this study
were as described previously [15]. To construct
pCMV-Myc-GST-XIAP, GST cDNA and XIAP cDNA, which was
obtained from HeLa cDNA library, were inserted in HindIII and
EcoRI/XhoI of pCMV-Myc [7], respectively.
2.3. Preparation of cell extract
Cells were lysed in buffer A (20 mM Tris–HCl (pH7.5), 10 mM
NaCl, 1 mM DTT, 0.5 mM PMSF, 0.5% NP-40) and placed on ice
for 10 min. After centrifugation at 15000 rpm, the supernatant
was used as the cell extract. To produce p-eRF3, cells were lysed
in buffer A supplemented with 2.5 mM CaCl2 (CaCl2-containing
buffer). The Western blot analysis, antibodies and protease inhibi-
tors used in this study were as described previously [15]. ALLN was
purchased from CALBIOCHEM.
2.4. Cell treatment
For treatment with stress-inducing reagents (tunicamycin,
thapsigargin, A23187 and etoposide), culture medium of SK-N-SH
cells was replaced with fresh culture medium and
stress-inducing reagents were then added. To examine the effects
of protease inhibitors (AEBSF, E-64, z-VAD-fml, MG132, lactacystin
(Calbiochem) and calpeptin (Sigma)), cells were pretreated with
protease inhibitors for 30 min, and then stress-inducing reagents
were added.
2.5. Puriﬁcation of recombinant proteins
For the preparation of XIAP, Myc-GST-XIAP-expressing
HEK293T cells were lysed in buffer B (20 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1% NP-40, 2.5 mM EDTA, 1 mM dithiothreitol,
0.5 mM PMSF, 2 lg/ml aprotinin, 2 lg/ml leupeptin and 2 lg/ml
pepstatin A) and cells were placed on ice for 30 min. The lysate
was centrifuged at 15000 rpm for 20 min at 4 C, and thesupernatant was incubated with Glutathione Sepharose beads
(GE Healthcare) for 1 h in a cold room. The resin was washed
3 times with buffer B. Proteins were eluted in buffer C (buffer
B + 10 mM glutathione) for 30 min in a cold room. For the prepara-
tion of eRF3, eRF3-FLAG-expressing HEK293T cells were lysed in
RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40,
1% Na-deoxycholate, 0.1% SDS, 0.5 mM EDTA, 1 mM dithiothreitol,
0.5 mM PMSF, 2 lg/ml aprotinin, 2 lg/ml leupeptin and 2 lg/ml
pepstatin A) and cells were placed on ice for 30 min. The lysate
was centrifuged at 15000 rpm for 20 min at 4 C and the super-
natant was incubated with anti-FLAG IgG agarose (Sigma) for 1 h
in a cold room. The resin was washed 3 times with RIPA buffer.
Proteins were eluted in buffer D (20 mM Tris–HCl (pH 7.5),
150 mM NaCl, 0.5% NP-40, 0.5 mM EDTA, 1 mM dithiothreitol,
150 ng/lL 3FLAG peptide (Sigma)) for 30 min in a cold room.
2.6. In vitro calpain-mediated cleavage assay
Puriﬁed eRF3-FLAG proteins and a combination of m-calpain
(Calbiochem) and 2.5 mM CaCl2 were incubated in buffer D
(50 mM Tris–HCl (pH 7.5), 100 mM NaCl, 0.5 mM EDTA, 1 mM
dithiothreitol, 10% glycerol) on ice.
3. Results
3.1. p-eRF3 is produced by calcium-dependent protease
During the course of investigating proteolytic cleavage of eRF3,
we noticed that eRF3 was cleaved in cell extracts that were pre-
pared using EDTA-free buffer. Thus we examined the effects of
divalent cations on the cleavage of eRF3 in cell extracts. THP-1 cells
were lysed with lysis buffer containing either 2.5 mM MgCl2 or
2.5 mM CaCl2, and the status of eRF3 in each cell extract was ana-
lyzed by Western blotting. Fig. 1A clearly shows that eRF3 was
cleaved in CaCl2-containing buffer, whereas eRF3 was not affected
in MgCl2-, EDTA- or EGTA-containing buffer. To verify that the pro-
cessed isoform of eRF3 (provisionally named eRF3-Ca2+) is p-eRF3,
we attempted to determine whether eRF3 is cleaved at the
N-terminal domain or the C-terminal domain. To this end, we pre-
pared cells expressing wild-type eRF3 (eRF3-wt) and 73A-eRF3
(p-eRF3), both of which are N-terminally ubiqutin (Ub)-tagged
and C-terminally FLAG-tagged [15]. As described previously, when
these eRF3 constructs were expressed in cells, the Ub moiety is
removed by multiple ATP-dependent proteases, and eRF3 frag-
ments without Ub can be produced [15]. The eRF3-wt-expressing
cells were lysed in CaCl2-containing buffer and C-terminally
FLAG-tagged eRF3 was detected by anti-FLAG antibody. Since
eRF3-Ca2+, as well as full-length eRF3, was recognized by
anti-FLAG antibody, eRF3-Ca2+ is produced by cleavage at the
N-terminal region of eRF3 (Fig. 1B). We also conﬁrmed that
eRF3-Ca2+ exhibited the same mobility on SDS–PAGE as that of
73A-eRF3 (p-eRF3). We previously reported another form of
cleaved eRF3 (eRF3-cp) that is produced by caspase-mediated
cleavage of eRF3, mainly at 32D [15]. To distinguish between
eRF3-Ca2+ and eRF3-cp, we next prepared cells expressing
33Q-eRF3 (eRF3-cp) and eRF3 (D25A/D29A/D32A/D35A), which is
resistant to the cleavage by caspases [15]. As shown in Fig. 1C, both
33Q-eRF3 (eRF3-cp) and eRF3 (D25A/D29A/D32A/D35A) were
cleaved in Ca2+-containing buffer. These results show that
eRF3-Ca2+ is a distinct isoform from eRF3-cp.
Because an important property of p-eRF3 is that it binds to IAPs
through its N-terminally exposed IAP-binding motif (IBM) [11,12],
we examined the interaction between eRF3-Ca2+ and XIAP. We pre-
pared cells expressing either eRF3 (wt) or eRF3(A73G) mutant,
both of which were C-terminally FLAG-tagged. The eRF3
Fig. 1. p-eRF3 is produced by calcium-dependent protease. (A) Cell extracts were prepared from THP-1 cells using lysis buffer supplemented with EDTA, EGTA, MgCl2 or CaCl2
(each at 2.5 mM). The status of eRF3 was analyzed by Western blotting using anti-eRF3 antibody. GAPDH was also analyzed using anti-GAPDH as a loading control. (B) THP-1
cells were electroporated with pCMV-MycFLAG-Ub-eRF3 and whole cell extracts were prepared using lysis buffer containing either EGTA (CaCl2) or CaCl2 (CaCl2+). Standard
sample of p-eRF3 prepared from HEK293T cells transfected with pCMV-MycFLAG-Ub-73A-eRF3 is indicated as 73A-eRF3 (p-eRF3). The status of eRF3 proteins was analyzed
by Western blotting using anti-FLAG antibodies. (C) THP-1 cells were electroporated with pCMV-MycFLAG-Ub-eRF3, eRF3 (D25A/D29A/D32A/D35A) or 33Q-eRF3 and whole-
cell extracts were prepared using lysis buffer containing either EGTA (CaCl2) or CaCl2 (CaCl2+). Western blotting was performed as described in Fig. 1B. (D) Illustration of
XIAP binding assay protocol. IP, immunoprecipitation. (E) THP-1 cells expressing FLAG-tagged eRF3 were lysed in EDTA or CaCl2 containing lysis buffer for preparation of full-
length eRF3 (WT (EDTA)) or eRF3-Ca2+ (WT (Ca2+)). The eRF3 proteins were immunoprecipitated using anti-FLAG antibody. As a negative control, FLAG-tagged eRF3 (A73G)
(Ca2+) was also prepared as above. eRF3 proteins were puriﬁed using anti-FLAG M2 agarose and mixed with Myc-tagged GST-XIAP. Pull down experiment was performed
using anti-FLAG antibody. * indicates immunoglobulin. (F) Schematic diagram of the interaction between IAP and eRF3 proteins.
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buffer to obtain full-length eRF3 or eRF3-Ca2+, respectively, and
eRF3(A73G)-expressing cells were lysed with Ca2+-containing buf-
fer. The eRF3 proteins were puriﬁed using anti-FLAG resin and then
mixed with Myc-tagged XIAPs (Fig. 1D). After rotation, pull-downassay was performed using anti-FLAG resin and interactions
between the eRF3 proteins and XIAP were analyzed by Western
blotting. As shown in Fig. 1E, only eRF3-Ca2+ but not full-length
eRF3 co-precipitated XIAP. The A73G mutation of eRF3 abolished
its interaction with XIAP, although the mutation did not affect
Fig. 2. p-eRF3 is produced in a calpain-dependent manner. (A) THP-1 cells were lysed in CaCl2-containing buffer supplemented with 0.5 mM PMSF and aprotinin, leupeptin or
pepstatin A (each at 2 lg/ml). PMSF was added to all samples to prevent unexpected degradation of eRF3. THP-1 cell extracts supplemented with or without all of the
proteases were also prepared. The status of eRF3 was analyzed by Western blotting using anti-eRF3 antibody. (B) THP-1 cells were lysed in CaCl2-containing buffer
supplemented with either E-64 or ALLN (each at 20 lM) and Western blotting was performed as described in Fig. 2A. (C) Flag-tagged eRF3 protein puriﬁed from eRF3-FLAG-
expressing HEK293T cells, was incubated with an indicated amounts of recombinant m-calpain on ice for 30 min. Flag-tagged eRF3 incubated with 2 lg/ml of recombinant m-
calpain for the indicated time periods were also prepared. (D) Intact eRF3-FLAG and calpain-mediated processed eRF3 (0.2 lg/ml of m-calpain for 30 min and 2 lg/ml m-
calpain for 5 min) were loaded with a standard sample of p-eRF3 (73A-eRF3) prepared as in Fig. 1B.
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for its binding to IAPs (Fig. 1F), the evidence strongly supports our
conclusion that eRF3-Ca2+ is p-eRF3.
3.2. p-eRF3 is produced in a calpain-dependent manner
To elucidate the protease(s) responsible for p-eRF3 (eRF3-Ca2+)
production, we tested the effects of protease inhibitors includingserine protease inhibitors PMSF and aprotinin, cysteine protease
inhibitor leupeptin and aspartyl protease inhibitor pepstatin A on
the cleavage of eRF3 in CaCl2-containing buffer (Fig. 2A). Among
the proteases tested, only leupeptin inhibited the cleavage of
eRF3, indicating that cysteine protease might be responsible for
the Ca2+-dependent cleavage of eRF3. Since calpain is a
well-known Ca2+-dependent cysteine protease, we next examined
another cysteine protease inhibitor, E-64, and also a speciﬁc
Fig. 3. Activation of calpain is necessary for the production of p-eRF3 in living cells. (A) SK-N-SH cells were treated with ER-stress inducers (1 lg/ml tunicamycin (TM), 1 lM
thapsigargin (TG) and 1 lg/ml A23187) and cultured for the indicated periods (24 h and 48 h). Cells without incubation were prepared as a control. The status of eRF3 was
analyzed by Western blotting using anti-eRF3 antibody. Endogenous GAPDH was detected as a loading control. (B) SK-N-SH cells were treated with either 1 lM thapsigargin
(TG) or 1 lg/ml A23187 in the presence of 20 lM z-VAD-fmk. Protease inhibitors (AEBSF (50 lg/ml), E-64 (50 lM), MG132 (10 lM), ALLN (20 lM) and lactacystin (5 lM))
were also added. (C) SK-N-SH cells were treated with etoposide and protease inhibitors (AEBSF (50 lg/ml), E-64 (50 lM), z-VAD-fmk (20 lM), MG132 (10 lM) and lactacystin
(5 lM)). Calpain speciﬁc inhibitor calpeptin (20 lM) was also tested. (D) Schematic representation of calpain-mediated processing of eRF3 into p-eRF3.
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pletely blocked the cleavage of eRF3. These results strongly suggest
that the Ca2+-dependent cleavage of eRF3 is mediated by calpain.
Essentially the same results were obtained using other cell types,
although the extent of the cleavage of eRF3 varied among cell types(data not shown). To conﬁrm that the Ca2+-dependent cleavage of
eRF3 is mediated by calpain, we examined whether recombinant
calpain cleaves eRF3. Puriﬁed eRF3 proteins were incubated with
recombinant m-calpain. A single cleaved isoform of eRF3 was pref-
erentially produced by the recombinant m-calpain (Fig. 2C),
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cause minor cleavages or degradation of eRF3. As expected, the
principal cleaved product of eRF3 exhibited the same mobility as
p-eRF3 (eRF3-Ca2+) on SDS–PAGE (Fig. 2D). From these results,
we conclude that calpain is responsible for the Ca2+-dependent
cleavage of eRF3.
3.3. Activation of calpain is necessary for the production of p-eRF3 in
living cells
We next examined whether p-eRF3 is produced in living cells
when calpain is activated. Because challenge with ER stress was
reported as one of the calpain-activating conditions [19,20], we
tested the status of eRF3 when cells were treated with tuni-
camycin, thapsigargin and A23187, which are commonly used as
ER-stress-inducing agents. Fig. 3 shows representative results of
p-eRF3 production under ER-stress conditions. When human neu-
roblastoma SK-N-SH cells were treated with the ER stressors, two
cleavage products corresponding to p-eRF3 and eRF3-cp were
detected, although only a modest effect was observed for tuni-
camycin (Fig. 3A). As reported previously, the upper band corre-
sponds to eRF3-cp, since the band was abrogated by the caspase
inhibitor zVAD.fmk (Fig. 3B). To ensure that the lower band corre-
sponds to p-eRF3, we examined the effect of protease inhibitors on
the production of p-eRF3 under condition that inhibits caspases by
zVAD.fmk (Fig. 3B). Calpain inhibitors E-64 and ALLN completely
abrogated the appearance of the lower band. The results are con-
sistent with the idea that the lower band corresponds to p-eRF3
and the production of p-eRF3 depends on calpain. Proteasome inhi-
bitor MG132, which is known to inhibit calpain [21], also blocked
the production of p-eRF3, whereas another proteasome inhibitor,
lactacystin, had no obvious effect. These results also support the
idea that the production of p-eRF3 is mediated by calpain [22].
Although the extent of p-eRF3 production varied depending on
the cell lines, p-eRF3 was reproducibly detected by the treatment
with ER stressors in several cell lines (data not shown).
Especially by the treatment with calcium ionophore A23187,
which is directly linked to calpain activation, p-eRF3 was observed
in almost all cell lines tested. p-eRF3 was also produced in a
calpain-dependent manner when SK-N-SH cells were treated with
the non-ER stressor etoposide (Fig. 3C). Thus, conditions leading to
p-eRF3 production are not limited to the challenge with ER stress.
Overall, these results indicate that the activation of calpain is nec-
essary for the production of p-eRF3.
4. Discussion
Previous studies suggested that eRF3 may function in the regu-
lation of cell death; processed eRF3 (p-eRF3) interacts with IAPs
through its IBM and is able to promote caspase activation, IAP
ubiquitination and apoptosis. However, lack of knowledge regard-
ing the conditions to produce p-eRF3 has hampered progress in
investigating the role of eRF3 in cell death. In this study, we have
demonstrated that calpain is responsible for the processing of
eRF3 into p-eRF3 (Fig. 3D), based on the following ﬁve features;
(i) Ca2+ dependence, (ii) sensitivity to cysteine protease inhibitors,
leupeptin and E-64, (iii) sensitivity to calpain-speciﬁc inhibitor
ALLN, (iv) the ability of the processed isoform of eRF3 to bind to
XIAP, and (v) the ability of recombinant m-calpain to process
eRF3 into p-eRF3. The ﬁnding that calpain is responsible for the
production of p-eRF3 provides a basis for understanding the role
of p-eRF3 in apoptosis (Fig. 3D).
Consistent with the apoptotic function of p-eRF3, the
pro-apoptotic functions of calpain are well established. Although
calpain is involved inmitochondria-dependent apoptosis, itwasalsoreported to activatemouse caspase-12 andhuman caspase-4,which
are crucial caspases for ‘mitochondria-independent ER-stress-
induced apoptosis’ [19,23]. ER-stress-induced apoptosis usually
crosstalks with mitochondria-dependent and mitochondria-
independent pathways [24,25], but in some cases, the contribution
of the mitochondrial pathway is not observed [26,27]. In the latter
cases, IAP-binding proteins including Smac/DIABLO and
Omi/HtrA2, which are located in the mitochondrial inner mem-
brane, cannot promote apoptosis. These observations are consistent
with the idea that p-eRF3, instead of Smac/DIABLO, Omi/HtrA2, is a
cytoplasmic IAP-binding protein that promotes
mitochondria-independent ER-stress-induced apoptosis (Fig. 3D).
Calpain is also known to regulate oncogenic stress-induced
apoptosis and senescence [28–30]. These functions of calpain
may provide a clue to understand the second physiological role
of p-eRF3 in apoptosis, since p-eRF3, which is devoid of an NES,
interacts with ARF tumor suppressor in the nucleus (Fig. 3D)
[14]. It is thus tempting to speculate that p-eRF3 mediates
calpain-activating signal to the nucleus, in which p-eRF3 might
regulate the function of ARF, a crucial regulator of
oncogene-related apoptosis and senescence [31,32].
Thus far, we have reported two types of cleaved isoforms of
eRF3, p-eRF3 [11,14] and eRF3-cp [15] (Fig. 3D). These cleaved
eRF3 isoforms are produced upstream or downstream of caspase
activation; p-eRF3 is produced by calpain to activate caspase
whereas eRF3-cp is produced as a result of caspase activation. A
relationship between the two isoforms of eRF3 is not clear at pre-
sent. However, our results show eRF3-cp might be a poor target of
calpain (Fig. 1C), suggesting that N-terminal residues of eRF3,
which are removed by caspase-mediated cleavage, support
calpain-mediated cleavage. Noteworthy, polyglycine expansions
included in this N-terminal region of eRF3 associates with cancer
susceptibility [33,34]. Thus it is tempting to speculate that polyg-
lycine expansions affect calpain-mediated cleavage and apoptosis,
and therefore cancer susceptibility. These possibilities are now
under investigation in our laboratory.
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